{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:28:12Z","timestamp":1786375692709,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejogrb.2026.115115","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:00:52Z","timestamp":1775782852000},"page":"115115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expert opinion by Federation of Obstetric and Gynaecological Societies of India on elagolix \u2212 Redefining the endometriosis therapy landscape"],"prefix":"10.1016","volume":"322","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-1119","authenticated-orcid":false,"given":"Sunita","family":"Tandulwadkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basab","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Ganpule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brajbala","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0005","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13590","article-title":"Endometriosis and inflammatory immune responses: Indian experience","volume":"89","author":"Gajbhiye","year":"2023","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208464","article-title":"Systematic review of quality of life measures in patients with endometriosis","volume":"14","author":"Bourdel","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejogrb.2026.115115_b0015","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3390\/ijms21082815","article-title":"Estrogen receptors and endometriosis","volume":"21","author":"Chantalat","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12905-023-02694-5","article-title":"Clinical factors associated with quality of life among women with endometriosis: a cross-sectional study","volume":"23","author":"Pontoppidan","year":"2023","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GRF.0000000000000292","article-title":"Medical management of endometriosis","volume":"60","author":"Rafique","year":"2017","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2026.115115_b0030","unstructured":"FOGSI-ICOG Good Clinical Practice Recommendations (GCPR) Updates in Endometriosis Management. [Cited 2025 September 16]. Available from: https:\/\/www.fogsi.org\/wp-content\/uploads\/2024\/11\/GCPR-Updates-in-Endometriosis-Management.pdf."},{"key":"10.1016\/j.ejogrb.2026.115115_b0035","unstructured":"Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: Endometriosis. Hum Reprod Open. 2022;2022(2):hoac009."},{"issue":"10","key":"10.1016\/j.ejogrb.2026.115115_b0040","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm12103388","article-title":"Understanding progestins: from basics to clinical applicability","volume":"12","author":"Garc\u00eda-S\u00e1enz","year":"2023","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.ejogrb.2026.115115_b0045","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.3390\/ijms24086992","article-title":"Progesterone resistance in endometriosis: current evidence and putative mechanisms","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115115_b0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jpag.2007.04.008","article-title":"Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis","volume":"20","author":"Divasta","year":"2007","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115115_b0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2019.8096","article-title":"A clinician's guide to the treatment of endometriosis with elagolix","volume":"30","author":"Leyland","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115115_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2024.104321","article-title":"Why do oestrogens matter: Systematic review and meta-analysis assessing GnRH antagonists, considering add-back therapy, for endometriosis-associated pain","volume":"49","author":"Viviano","year":"2024","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0070","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/jcm12031008","article-title":"Gonadotropin-releasing hormone antagonists-a new hope in endometriosis treatment?","volume":"12","author":"Rzewuska","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejogrb.2026.115115_b0075","unstructured":"Orilissa PI. Highlights of prescribing information. [Cited 2025 September 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210450s000lbl.pdf."},{"key":"10.1016\/j.ejogrb.2026.115115_b0080","unstructured":"AbbVie. AbbVie receives Health Canada approval of ORILISSA\u2122 (elagolix) for the treatment of moderate to severe pain associated with endometriosis. [Cited 2025 September 16]. Available from: https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/press-releases\/2018-Oct-5_Elagolix-Health-Canada-Release_EN.pdf."},{"key":"10.1016\/j.ejogrb.2026.115115_b0085","unstructured":"Recommendations of the SEC (Reproductive) made in its 02nd\/24 meeting held on 20.03.2024 at CDSCO (HQ), New Delhi. [Cited 2025 September 16]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Reproductive%20dated%2020.03.2024.pdf."},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115115_b0090","doi-asserted-by":"crossref","first-page":"630.e1","DOI":"10.1016\/j.ajog.2024.06.040","article-title":"Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial","volume":"231","author":"Miller","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115115_b0095","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jc.2016-3845","article-title":"Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women","volume":"102","author":"Ng","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2026.115115_b0110","first-page":"3","article-title":"Efficacy and safety of elagolix in endometriosis: Phase-III randomized double-blind active-controlled trial BJOG-An","volume":"131","author":"Gupta","year":"2024","journal-title":"Int J Obs and Gynae"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.fertnstert.2019.02.031","article-title":"Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis","volume":"112","author":"Surrey","year":"2019","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/AOG.0000000000003917","article-title":"Health-related quality of life improvements in patients with endometriosis treated with elagolix","volume":"136","author":"Taylor","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115115_b0125","doi-asserted-by":"crossref","first-page":"592.e1","DOI":"10.1016\/j.ajog.2019.11.1255","article-title":"Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials","volume":"222","author":"Pokrzywinski","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ejogrb.2026.115115_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10401","article-title":"Estimating the effect of elagolix treatment for endometriosis on postmenopausal bone outcomes: a model bridging phase III trials to an older real-world population","volume":"4","author":"Kilpatrick","year":"2020","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-019-00840-7","article-title":"Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis","volume":"59","author":"Shebley","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.ejogrb.2026.115115_b0140","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/1933719114549848","article-title":"Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density","volume":"21","author":"Carr","year":"2014","journal-title":"Reprod Sci"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/humrep\/dey368","article-title":"\u2018Luigi mangiagalli\u2019 endometriosis study group. elagolix for endometriosis: all that glitters is not gold","volume":"34","author":"Vercellini","year":"2019","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.fertnstert.2017.01.003","article-title":"Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills","volume":"107","author":"Casper","year":"2017","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/humupd\/dmq042","article-title":"Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis","volume":"17","author":"Vercellini","year":"2011","journal-title":"Hum Reprod Update"},{"issue":"8","key":"10.1016\/j.ejogrb.2026.115115_b0160","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/humrep\/der156","article-title":"Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis","volume":"26","author":"Chapron","year":"2011","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115115_b0165","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.tjog.2024.07.015","article-title":"Long-term dienogest treatment in endometriosis: consensus from Taiwanese experts","volume":"63","author":"Liu","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115115_b0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.fertnstert.2007.12.080","article-title":"Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis\u2014A randomized, double-blind, multicenter, controlled trial","volume":"91","author":"Harada","year":"2009","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/aogs.13969","article-title":"Risk factors for non-response and discontinuation of dienogest in endometriosis patients: a cohort study","volume":"100","author":"Nirgianakis","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"16","key":"10.1016\/j.ejogrb.2026.115115_b0180","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2165\/11206320-000000000-00000","article-title":"Dienogest: a review of its use in the treatment of endometriosis","volume":"70","author":"McCormack","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejogrb.2026.115115_b0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IJWH.S77202","article-title":"Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program","volume":"7","author":"Strowitzki","year":"2015","journal-title":"Int J Womens Health"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115115_b0190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s13224-024-02097-y","article-title":"Recent trends in medical management of endometriosis","volume":"74","author":"Patel","year":"2024","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.ejogrb.2026.115115_b0195","unstructured":"LUPRON DEPOT PI. [Cited 2025 September 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/019732s045,020517s043lbl.pdf."},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115115_b0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/cer-2018-0124","article-title":"Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA","volume":"8","author":"Wang","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115115_b0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jval.2018.12.010","article-title":"Patient preferences for endometriosis pain treatments in the United States","volume":"22","author":"Poulos","year":"2019","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0210","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/AOG.0000000000005923","article-title":"Pharmacologic interventions for endometriosis-related pain: a systematic review and meta-analysis","volume":"146","author":"Kou","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.ejogrb.2026.115115_b0215","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/OGX.0000000000000346","article-title":"The impact of adenomyosis on women's fertility","volume":"71","author":"Harada","year":"2016","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115115_b0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12905-022-01596-2","article-title":"Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis","volume":"22","author":"Muhammad","year":"2022","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ejogrb.2026.115115_b0225","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejogrb.2020.02.027","article-title":"Elagolix to medically treat a uterine adenomyoma: a case report","volume":"247","author":"Kavoussi","year":"2020","journal-title":"Europ J Obs Gyn Rep Bio"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115115_b0230","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2741\/E648","article-title":"Recurrence of endometrioma after laparoscopic excision and its prevention by medical management","volume":"5","author":"Koga","year":"2013","journal-title":"Front Biosci (Elite Ed)"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152600182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152600182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:35:32Z","timestamp":1786372532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121152600182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S030121152600182X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115115","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion by Federation of Obstetric and Gynaecological Societies of India on elagolix \u2212 Redefining the endometriosis therapy landscape","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115115"}}